Difference between revisions of "Mitomycin (Mutamycin)"
Jump to navigation
Jump to search
m |
|||
| (28 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.<ref name="insert">[http:// | + | Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.<ref name="insert">[http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-251-01%20MIT%205MG/5539025101 Mitomycin (Mutamycin) package insert]</ref><ref>[[:File:Mitomycin.pdf | Mitomycin (Mutamycin) package insert (locally hosted backup)]]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Anal cancer]] | *[[Anal cancer]] | ||
*[[Bladder cancer]] | *[[Bladder cancer]] | ||
| + | *[[Breast cancer]] | ||
*[[Cervical cancer]] | *[[Cervical cancer]] | ||
| + | *[[Cholangiocarcinoma]] | ||
| + | *[[Colorectal cancer]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
| − | *[[ | + | **[[Esophageal adenocarcinoma]] |
| + | *[[Gallbladder cancer]] | ||
| + | *[[Gastric cancer]] | ||
| + | *[[Head and neck cancer]] | ||
| + | |||
| + | ==Diseases for which is was used== | ||
| + | *[[Non-small cell lung cancer_-_historical|Non-small cell lung cancer]] | ||
| + | *[[Pancreatic cancer - historical|Pancreatic cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://chemocare.com/bio/mitomycin.asp Mitomycin (Mutamycin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/mitomycin.asp Mitomycin (Mutamycin) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/mitomycin.asp Mitomycin (Mutamycin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/mitomycin.asp Mitomycin (Mutamycin) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/mitomycin-patient-drug-information Mitomycin (Mutamycin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/mitomycin-patient-drug-information Mitomycin (Mutamycin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/mitomycin-patient-drug-information Mitomycin (Mutamycin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/mitomycin-patient-drug-information Mitomycin (Mutamycin) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *1974: Initial FDA approval for use in [[Gastric cancer|gastric]] and [[Pancreatic cancer|pancreatic carcinomas]] when combined with other chemotherapeutic agents. | ||
| + | *Uncertain date: Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated [[Gastric cancer|adenocarcinoma of the stomach]] or [[Pancreatic cancer|pancreas]] in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. ''(No supporting studies are cited)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *1962-10-05: EURD | ||
| + | ==Also known as== | ||
| + | *'''Generic names:''' mitomycin-C, MTC | ||
| + | *'''Brand names:''' Lyomit, Mitocin, Mitocyte, Mitosol, Mitozytrex, Mutamycin | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | [[Category:Intravesical medications]] | ||
| + | [[Category:Vesicant]] | ||
| + | |||
| + | [[Category:Antitumor antibiotics]] | ||
| + | [[Category:Human DNA synthesis inhibitors]] | ||
| + | |||
| + | [[Category:Anal cancer medications]] | ||
| + | [[Category:Bladder cancer medications]] | ||
| + | [[Category:Breast cancer medications]] | ||
| + | [[Category:Cervical cancer medications]] | ||
| + | [[Category:Cholangiocarcinoma medications]] | ||
| + | [[Category:Colorectal cancer medications]] | ||
| + | [[Category:Esophageal adenocarcinoma medications]] | ||
| + | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Gallbladder cancer medications]] | ||
| + | [[Category:Gastric cancer medications]] | ||
| + | [[Category:Head and neck cancer medications]] | ||
| + | |||
| + | [[Category:Non-small cell lung cancer medications (historic)]] | ||
| + | [[Category:Pancreatic cancer medications (historic)]] | ||
| + | |||
| + | [[Category:FDA approved in 1974]] | ||
| + | [[Category:EMA approved in 1962]] | ||
Revision as of 02:07, 12 January 2024
General information
Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Anal cancer
- Bladder cancer
- Breast cancer
- Cervical cancer
- Cholangiocarcinoma
- Colorectal cancer
- Esophageal cancer
- Gallbladder cancer
- Gastric cancer
- Head and neck cancer
Diseases for which is was used
Patient drug information
- Mitomycin (Mutamycin) patient drug information (Chemocare)[3]
- Mitomycin (Mutamycin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1974: Initial FDA approval for use in gastric and pancreatic carcinomas when combined with other chemotherapeutic agents.
- Uncertain date: Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. (No supporting studies are cited)
History of changes in EMA indication
- 1962-10-05: EURD
Also known as
- Generic names: mitomycin-C, MTC
- Brand names: Lyomit, Mitocin, Mitocyte, Mitosol, Mitozytrex, Mutamycin
References
Categories:
- Drugs
- Intravenous medications
- Intravesical medications
- Vesicant
- Antitumor antibiotics
- Human DNA synthesis inhibitors
- Anal cancer medications
- Bladder cancer medications
- Breast cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Colorectal cancer medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Gallbladder cancer medications
- Gastric cancer medications
- Head and neck cancer medications
- Non-small cell lung cancer medications (historic)
- Pancreatic cancer medications (historic)
- FDA approved in 1974
- EMA approved in 1962